Premium
Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection
Author(s) -
Neff Guy W.,
O'Brien Christopher B.,
Nery Jose,
Shire Norah J.,
Nishida Seigo,
delaGarza Julia,
Montalbano Marzia,
Safdar Kamran,
Ruiz Phillip,
Rideman Eric,
Gascon Jose A.,
Tzakis Andreas G.,
Madariaga Juan,
Rudich Steven M.
Publication year - 2004
Publication title -
liver transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.814
H-Index - 150
eISSN - 1527-6473
pISSN - 1527-6465
DOI - 10.1002/lt.20301
Subject(s) - medicine , liver transplantation , incidence (geometry) , gastroenterology , jaundice , retrospective cohort study , hepatitis c , medical record , surgery , hepatitis c virus , transplantation , immunology , virus , physics , optics
Abstract Hepatitis C virus (HCV) is becoming the most common indication for liver retransplantation (ReLTx). This study was a retrospective review of the medical records of liver transplant patients at our institution to determine factors that would identify the best candidates for ReLTx resulting from allograft failure because of HCV recurrence. The patients were divided into 2 groups on the basis of indication for initial liver transplant. Group 1 included ReLTx patients whose initial indication for LTx was HCV. Group 2 included patients who received ReLTx who did not have a history of HCV. We defined chronic allograft dysfunction (AD) as patients with persistent jaundice (> 30 days) beginning 6 months after primary liver transplant in the absence of other reasons. HCV was the primary indication for initial orthotopic liver transplantation (OLT) in 491/1114 patients (44%) from July 1996 to February 2004. The number of patients with AD undergoing ReLTx in Groups 1 and 2 was 22 and 12, respectively. The overall patient and allograft survival at 1 year was 50% and 75% in Groups 1 and 2, respectively ( P = .04). The rates of primary nonfunction and technical problems after ReLTx were not different between the groups. However, the incidence of recurrent AD was higher in Group 1 at 32% versus 17% in Group 2 ( P = .04). Important factors that predicted a successful ReLTx included physical condition at the time of ReLTx ( P = .002) and Child‐Turcotte‐Pugh score ( P = .008). In conclusion, HCV is associated with an increased incidence of chronic graft destruction with a negative effect on long‐term results after ReLTx. The optimum candidate for ReLTx is a patient who can maintain normal physical activity. As the allograft shortage continues, the optimal use of cadaveric livers continues to be of primary importance. The use of deceased donor livers in patients with allograft failure caused by HCV remains a highly controversial issue. (Liver Transpl 2004;10:1497–1503.)